Selecta Biosciences price target lowered to $12 from $28 at Needham. Needham analyst Chad lowered his price target on Selecta Biosciences to $12 to reflect the impact of equity dilution from the company’s recent financing and also the longer timeframe for the launch of its SEL-212 product. Longer term, the analyst keeps his Buy rating on Selecta Biosciences based on the potential for SEL-212 to succeed in clinical trials for refractory and tophaceous gout and for its possibility of “bringing additional SVP programs to the clinic.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.